丙型肝炎病毒（HCV）和人类免疫缺陷病毒（HIV）药物之间的药物相互作用。
Drug-Drug Interactions Among Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV) Medications.
机构信息
St John Fisher College Wegmans School of Pharmacy, Rochester, NY, USA.
出版信息
Infect Dis Ther. 2015 Jun;4(2):159-72. doi: 10.1007/s40121-015-0061-2. Epub 2015 Apr 21.
Abstract
One-fourth of individuals diagnosed with the human immunodeficiency virus concomitantly have the hepatitis C virus infection. Since the discovery of highly active antiretroviral therapy, liver complications have become the leading cause of morbidity and mortality in HIV-HCV coinfected individuals. Optimal treatment in this patient population is critical, as coinfection has been linked to deterioration of both disease states. The objective of this review article is to highlight the current literature on drug-drug interactions between HIV and HCV treatments. The management of the treatment of coinfection patients has been covered extensively in numerous other publications.
摘要
四分之一被诊断患有人类免疫缺陷病毒的个体同时患有丙型肝炎病毒感染。自从发现高效抗逆转录病毒疗法以来，肝脏并发症已成为 HIV-HCV 合并感染个体发病率和死亡率的主要原因。在这一患者群体中，最佳治疗至关重要，因为合并感染与两种疾病状态的恶化有关。本文的目的是强调关于 HIV 和 HCV 治疗之间药物相互作用的现有文献。合并感染患者的治疗管理已在许多其他出版物中进行了广泛讨论。
相似文献
1
Drug-Drug Interactions Among Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV) Medications.丙型肝炎病毒（HCV）和人类免疫缺陷病毒（HIV）药物之间的药物相互作用。
Infect Dis Ther. 2015 Jun;4(2):159-72. doi: 10.1007/s40121-015-0061-2. Epub 2015 Apr 21.
2
Management of HIV and hepatitis virus coinfection.HIV 和肝炎病毒合并感染的管理。
Expert Opin Pharmacother. 2010 Oct;11(15):2497-516. doi: 10.1517/14656566.2010.500615.
3
Treatment of hepatitis C in HIV-coinfected patients.HIV合并感染患者的丙型肝炎治疗。
Ann Pharmacother. 2006 Mar;40(3):479-89; quiz 582-3. doi: 10.1345/aph.1G427. Epub 2006 Feb 28.
4
A case of successful hepatitis C virus eradication by 24 weeks of telaprevir-based triple therapy for a hemophilia patient with hepatitis C virus/human immunodeficiency virus co-infection who previously failed pegylated interferon-α and ribavirin therapy.一名丙型肝炎病毒/人类免疫缺陷病毒合并感染的血友病患者，此前聚乙二醇化干扰素-α和利巴韦林治疗失败，采用基于特拉匹韦的三联疗法进行24周治疗后成功根除丙型肝炎病毒的病例。
J Infect Chemother. 2014 May;20(5):320-4. doi: 10.1016/j.jiac.2013.11.006. Epub 2014 Jan 27.
5
Influence of coinfection with hepatitis C virus on morbidity and mortality due to human immunodeficiency virus infection in the era of highly active antiretroviral therapy.在高效抗逆转录病毒治疗时代，丙型肝炎病毒合并感染对人类免疫缺陷病毒感染所致发病率和死亡率的影响。
Clin Infect Dis. 2003 Feb 1;36(3):363-7. doi: 10.1086/345953. Epub 2003 Jan 14.
6
Human immunodeficiency virus and hepatitis C virus coinfection: epidemiology, natural history, therapeutic options and clinical management.人类免疫缺陷病毒与丙型肝炎病毒合并感染：流行病学、自然史、治疗选择及临床管理
Infection. 2004 Feb;32(1):33-46. doi: 10.1007/s15010-004-3063-7.
7
Coinfection with human immunodeficiency virus and hepatitis C virus: challenges and therapeutic advances. Insights from the Society of Infectious Diseases Pharmacists.人免疫缺陷病毒和丙型肝炎病毒合并感染：挑战与治疗进展。感染病药学学会的观点。
Pharmacotherapy. 2011 Apr;31(4):357-68. doi: 10.1592/phco.31.4.357.
8
Hepatitis C and human immunodeficiency virus coinfections.丙型肝炎与人类免疫缺陷病毒合并感染。
J Clin Gastroenterol. 2001 Nov-Dec;33(5):367-74. doi: 10.1097/00004836-200111000-00005.
9
Drug interactions between psychoactive substances and antiretroviral therapy in individuals infected with human immunodeficiency and hepatitis viruses.感染人类免疫缺陷病毒和肝炎病毒个体中精神活性物质与抗逆转录病毒疗法之间的药物相互作用。
Subst Use Misuse. 2006;41(10-12):1395-463. doi: 10.1080/10826080600846235.
10
Treatment of the hepatitis C virus in patients coinfected with HIV.同时感染艾滋病毒的丙型肝炎病毒患者的治疗。
Gastroenterol Clin North Am. 2004 Sep;33(3):479-96, vii-viii. doi: 10.1016/j.gtc.2004.04.002.
引用本文的文献
1
Drug interactions in people with HIV treated with antivirals for other viral illnesses.感染人类免疫缺陷病毒（HIV）的患者在接受抗病毒药物治疗其他病毒性疾病时的药物相互作用。
Expert Opin Drug Metab Toxicol. 2025 Apr;21(4):383-397. doi: 10.1080/17425255.2025.2455401. Epub 2025 Jan 23.
2
Structure-Based Drug Design of RdRp Inhibitors against SARS-CoV-2.基于结构的 RdRp 抑制剂对 SARS-CoV-2 的药物设计。
Top Curr Chem (Cham). 2023 Jun 15;381(5):22. doi: 10.1007/s41061-023-00432-x.
3
Direct antiviral agents (DAAs) and their use in pregnant women with hepatitis C (HCV).直接抗病毒药物（DAA）及其在丙型肝炎（HCV）孕妇中的应用。
Expert Rev Anti Infect Ther. 2022 Nov;20(11):1413-1424. doi: 10.1080/14787210.2022.2125868. Epub 2022 Sep 20.
4
Evaluation of the Potency of Anti-HIV and Anti-HCV Drugs to Inhibit P-Glycoprotein Mediated Efflux of Digoxin in Caco-2 Cell Line and Human Precision-Cut Intestinal Slices.抗HIV和抗HCV药物抑制P-糖蛋白介导的地高辛在Caco-2细胞系和人精密切割肠片中流出的效能评估。
Pharmaceuticals (Basel). 2022 Feb 18;15(2):242. doi: 10.3390/ph15020242.
5
Influence of drug-drug interactions on effectiveness and safety of direct-acting antivirals against hepatitis C virus.药物相互作用对直接作用抗病毒药物治疗丙型肝炎病毒的疗效和安全性的影响。
Eur J Hosp Pharm. 2021 Jan;28(1):16-21. doi: 10.1136/ejhpharm-2019-001889. Epub 2019 Jun 13.
6
Anti-HIV and Anti-Hepatitis C Virus Drugs Inhibit P-Glycoprotein Efflux Activity in Caco-2 Cells and Precision-Cut Rat and Human Intestinal Slices.抗 HIV 和抗丙型肝炎病毒药物抑制 Caco-2 细胞和精密切割大鼠及人肠切片中的 P-糖蛋白外排活性。
Antimicrob Agents Chemother. 2019 Oct 22;63(11). doi: 10.1128/AAC.00910-19. Print 2019 Nov.
7
Glomerular filtration rate change during chronic hepatitis C treatment with Sofosbuvir/Ledipasvir in HCV/HIV Coinfected patients treated with Tenofovir and a boosted protease inhibitor: an observational prospective study.在接受替诺福韦和增效蛋白酶抑制剂治疗的 HCV/HIV 合并感染患者中，使用 Sofosbuvir/Ledipasvir 治疗慢性丙型肝炎期间肾小球滤过率的变化：一项观察性前瞻性研究。
BMC Infect Dis. 2018 Aug 3;18(1):364. doi: 10.1186/s12879-018-3278-3.
8
Ledipasvir/sofosbuvir for treatment of hepatitis C virus in sofosbuvir-experienced, NS5A treatment-naïve patients: Findings from two randomized trials.来迪派韦索磷布韦治疗索磷布韦经治、无 NS5A 治疗史的丙型肝炎病毒感染患者：两项随机试验结果。
Liver Int. 2018 Jun;38(6):1010-1021. doi: 10.1111/liv.13616. Epub 2017 Dec 5.
本文引用的文献
1
Pharmacokinetic interaction between etravirine or rilpivirine and telaprevir in healthy volunteers: A randomized, two-way crossover trial.健康志愿者中依曲韦林或利匹韦林与替拉那韦之间的药代动力学相互作用：一项随机、双向交叉试验。
J Clin Pharmacol. 2014 May;54(5):563-73. doi: 10.1002/jcph.245.
2
Ombitasvir, paritaprevir co-dosed with ritonavir, dasabuvir, and ribavirin for hepatitis C in patients co-infected with HIV-1: a randomized trial.奥比他韦、帕利瑞韦与利托那韦联合达沙布韦和利巴韦林治疗 HIV-1 合并丙型肝炎病毒感染患者的随机试验。
JAMA. 2015;313(12):1223-31. doi: 10.1001/jama.2015.1328.
3
Safety and efficacy of ombitasvir - 450/r and dasabuvir and ribavirin in HCV/HIV-1 co-infected patients receiving atazanavir or raltegravir ART regimens.奥比他韦-450/r、达沙布韦及利巴韦林在接受阿扎那韦或拉替拉韦抗逆转录病毒治疗方案的HCV/HIV-1合并感染患者中的安全性和疗效
J Int AIDS Soc. 2014 Nov 2;17(4 Suppl 3):19500. doi: 10.7448/IAS.17.4.19500. eCollection 2014.
4
Simeprevir for the treatment of hepatitis C virus infection.西米普明用于治疗丙型肝炎病毒感染。
Pharmgenomics Pers Med. 2014 Aug 14;7:241-9. doi: 10.2147/PGPM.S52715. eCollection 2014.
5
ABT-450/r-ombitasvir and dasabuvir with or without ribavirin for HCV.ABT-450/r-ombitasvir 和 dasabuvir 联合或不联合利巴韦林治疗 HCV。
N Engl J Med. 2014 May 22;370(21):1983-92. doi: 10.1056/NEJMoa1402338. Epub 2014 May 4.
6
ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis.ABT-450/r-ombitasvir 和 dasabuvir 联合利巴韦林治疗肝硬化合并丙型肝炎。
N Engl J Med. 2014 May 22;370(21):1973-82. doi: 10.1056/NEJMoa1402869. Epub 2014 Apr 11.
7
Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin.ABT-450/r-ombitasvir 和利巴韦林联合治疗 HCV。
N Engl J Med. 2014 Apr 24;370(17):1594-603. doi: 10.1056/NEJMoa1315722. Epub 2014 Apr 10.
8
Retreatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin.ABT-450/r-ombitasvir 和 dasabuvir 联合利巴韦林治疗 HCV。
N Engl J Med. 2014 Apr 24;370(17):1604-14. doi: 10.1056/NEJMoa1401561. Epub 2014 Apr 10.
9
Efficacy of nucleotide polymerase inhibitor sofosbuvir plus the NS5A inhibitor ledipasvir or the NS5B non-nucleoside inhibitor GS-9669 against HCV genotype 1 infection.核苷酸聚合酶抑制剂索非布韦联合 NS5A 抑制剂来迪派韦或 NS5B 非核苷抑制剂 GS-9669 治疗 HCV 基因 1 型感染的疗效。
Gastroenterology. 2014 Mar;146(3):736-743.e1. doi: 10.1053/j.gastro.2013.11.007. Epub 2013 Nov 18.
10
Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, phase 2 trial.索磷布韦和来迪派韦固定剂量复方与利巴韦林联合或不联合用于初治和经治的基因 1 型丙型肝炎病毒感染患者（LONESTAR）：一项开放标签、随机、2 期临床试验。
Lancet. 2014 Feb 8;383(9916):515-23. doi: 10.1016/S0140-6736(13)62121-2. Epub 2013 Nov 5.
Zotero 插件